Agilent Advanced Therapeutics Click to Edit Master Title Style Strategic Growth in Specialty CDMO March 27, 2026 Click to edit Master subtitle style Safe harbor This presentation contains forward-looking statements (including, without limitation, statements on Agilent's (the "company" or "our") strategy, priorities, growth and growth opportunities, productivity, reinvestment, customer focus, evolving product mix, work environment and innovation plans; our revenue, revenue growth, operating margin and margin ...

Lonza Group Update Summary Company Overview - **Company**: Lonza Group (OTCPK:LZAG.Y) - **Event**: Update call regarding the divestment of the Capsules & Health Ingredients (CHI) business to Lone Star Key Points from the Call Divestment Details - Lonza has agreed to divest 60% of its CHI business to Lone Star for an enterprise value of CHF 2.3 billion, with expected total proceeds at or above CHF 3 billion, approximately $4 billion [3][10][12] - The upfront cash proceeds for Lonza will be CHF 1.7 billion, while retaining a 40% stake in CHI without management control [10][12] - The divestment is part of Lonza's strategy to transform into a pure play Contract Development and Manufacturing Organization (CDMO) [2][5] Strategic Rationale - The divestment is seen as a significant step in Lonza's transformation journey, allowing the company to focus on its core CDMO business [2][6] - Lonza aims to create value through a clearly defined capital allocation framework, focusing on organic growth and bolt-on M&A [14][18] - The CHI business was deemed not to benefit from the "Lonza Engine" to the same degree as other businesses, prompting the decision to divest [5][6] Market Position and Growth - Lonza targets a market worth around $100 billion with an underlying growth rate of 8%-10% [8] - The company expects to achieve CDMO sales growth of 11%-12% in 2026, with CORE EBITDA margins expanding above 32% [21] - The Lonza Engine is expected to add an incremental 2%-3% to the underlying market growth [21] Future Plans and Investments - Proceeds from the CHI divestment will be used for targeted organic growth opportunities and acquisitions with strong strategic fit [14][16] - Lonza plans to invest CHF 7 billion in organic growth by 2030, with additional funds available for bolt-on M&A [18] - The U.S. will remain a focus for future investments, particularly in integrated biologics and advanced synthesis [18][19] Financial Implications - The transaction will trigger an estimated CHF 1.3 billion non-cash impairment to be booked in 2025 [11] - Lonza's leverage will be materially below target levels post-sale, allowing for a share buyback of CHF 500 million [15][16] - The company will maintain a disciplined approach to capital allocation, returning surplus capital to shareholders when appropriate [17][22] Market Dynamics and Competitive Edge - Lonza's competitive edge lies in its unique strengths, referred to as the "Lonza Engine," which supports its market leadership in the CDMO sector [4][9] - The company is committed to remaining a well-diversified multimodality CDMO, investing across existing platforms and emerging technologies [17][18] Questions and Clarifications - The call included a Q&A session addressing valuation concerns, exit strategies for the retained stake, and the impact of the divestment on future financials [24][34][50] - Lonza's retained stake in CHI is expected to provide significant upside based on typical private equity returns over a holding period of 5-7 years [29][37] Conclusion - The divestment of the CHI business marks a pivotal moment in Lonza's strategy to solidify its position as a leading CDMO, with a clear focus on value creation and growth in the pharmaceutical manufacturing sector [21][22]

Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [2] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [2] Upcoming Investor Conferences - Lifecore management will participate in the Morgan Stanley 23 Annual Global Healthcare Conference from September 8-10, 2025, with a fireside chat scheduled for September 9, 2025, from 4:50 to 5:25 p.m. Eastern [3] - The company will also participate in the Barrington Research Virtual Fall Investment Conference on September 16, 2025, and the Jefferies CDMO Summit 2025 on September 17, 2025, in London, UK [3] Investor Engagement - A live webcast of the Morgan Stanley fireside chat will be accessible via Lifecore's investor website, with a replay available after the conference [1][3]